Cynapsus Therapeutics Completes $25,, Short Form Prospectus Offering
Find out all the key statistics for CYNAPSUS THERAPEUTICS INC (ordendelsantosepulcro.info), including valuation Ex-Dividend Date 4, N/A. Last Split Factor (new per old) 2. Cynapsus Therapeutics Completes $25,, Short Form support for the Offering confirms the results of our research to date, the validity of. On November 19, , Cynapsus Therapeutics Inc. (CYNAF) (CTH. 35 centers through North America, with a target start date of June
Based on the above corporate and contractual escrow agreements, 1, Common shares will be released upon closing, such that 24, of the 26, Common shares remain in escrow. Of the 1, Common shares to be released,Common shares are to be released to Mr.
ordendelsantosepulcro.info Historical Prices | CYNAPSUS THERAPEUTICS INC Stock - Yahoo Finance
All released Common shares are subject to a 4-month hold period. After the closing of the Transaction, 15, Common Shares, being In the event of a sale of the Corporation, including but not limited to a sale of substantially all of the assets of the Corporation, a merger or acquisition or a plan of arrangement, or whereby a new controlling shareholder is established, all shares then remaining in escrow would be immediately released.
About Cynapsus Therapeutics Cynapsus is a specialty pharmaceutical company developing an improved dosing formulation of an approved drug used to treat the symptoms of Parkinson's disease. Parkinson's disease is a chronic and progressive neurodegenerative disease that impacts motor activity, and its prevalence is increasing with the aging of the population.
It is estimated that between 25 percent and 50 percent of patients experience "off episodes" in which they have impaired movement or speaking capabilities. Current medications only control the disease's symptoms, and most drugs become less effective over time as the disease progresses. Cynapsus' lead drug candidate, APL, is an easy-to-administer, fast-acting and oral reformulation of an approved drug, apomorphine, used to rescue patients from off episodes.
Cynapsus is focused on rapidly maximizing the value of APL by completing pivotal studies in advance of a New Drug Application expected to be submitted in or Results demonstrated patients' mean time to full ON of 24 minutes and mean duration of ON of 50 minutes. The second poster presentation discusses safety data from the same trial.
The safety conclusions of this study indicated that APL was generally well-tolerated. Most adverse events "AE"s were mild to moderate in severity, there were no discontinuations due to an AE, and there was no apparent dose-response relationship with AEs observed.
Cynapsus Therapeutics Announces Completed Acquisition of Adagio Pharmaceuticals
The third poster looks at the effects of sublingual apomorphine by disease severity on the acute management of OFF episodes in PD. The posters will be accessible from Cynapsus' corporate website at www. The efficacy and safety data across a range of patients provide important insights on how our product candidate could be used to improve patient care," said Albert Agro, Ph.
We anticipate that these data will be used to file our new drug application "NDA" near the end of or in early The Company has successfully completed a Phase 2 clinical trial for its product candidate, APL, a sublingual formulation of apomorphine hydrochloride, or apomorphine.
Apomorphine is the only molecule approved for acute, intermittent treatment of OFF episodes for advanced PD patients, but is currently only approved as a subcutaneous injection in the United States. APL is a "turning ON" medication designed to rapidly, safely and reliably convert a PD patient from the OFF to the ON state while avoiding many of the issues associated with subcutaneous delivery of apomorphine.